Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
CAR-Tumor M01
- Development stage
- Phase 1
- Lead developer
- Joint Biosciences
- Modality
- Oncolytic Viruses → Oncolytic Therapeutics, Gene Therapies
- Administration
- Intramuscular, Intraperitoneal, Intratumoral, Intravenous, Subcutaneous
01
Overview
CAR-Tumor M01 is an in vivo chimeric antigen receptor (CAR) tumor cell therapy being developed by Rongrui Medicine (Joint Biosciences) in collaboration with the Cancer Institute and Hospital, Chinese Academy of Medical Sciences. It utilizes a genetically engineered vesicular stomatitis virus (VSV) vector platform to deliver a CAR transgene (such as an anti-CD3 CAR) directly into tumor cells. Upon infection, the tumor cells express the CAR on their outer membrane, which binds to CD3 on T cells, thereby recruiting and activating the patient's own T cells to target and destroy the tumor cells. This approach essentially reprograms the tumor cells to act as 'drug factories' and trigger localized, precise immune destruction of the tumor. CAR-Tumor M01 is currently in Phase I clinical development for the treatment of advanced malignant solid tumors.
- Other names
- CAR-Tumor M01 injection
02
Targets
LDLR (Low-density lipoprotein receptor)CD3 (T-cell surface glycoprotein CD3)
Beyond the preview
Go deeper on CAR-Tumor M01.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on CAR-Tumor M01.